116 related articles for article (PubMed ID: 8903952)
21. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
22. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man.
Bakker WH; Krenning EP; Breeman WA; Kooij PP; Reubi JC; Koper JW; de Jong M; Laméris JS; Visser TJ; Lamberts SW
J Nucl Med; 1991 Jun; 32(6):1184-9. PubMed ID: 1646302
[TBL] [Abstract][Full Text] [Related]
23. Intraoperative detection and resection of occult neuroblastoma: a technique exploiting somatostatin receptor expression.
Martinez DA; O'Dorisio MS; O'Dorisio TM; Qualman SJ; Caniano DA; Teich S; Besner GE; King DR
J Pediatr Surg; 1995 Nov; 30(11):1580-9. PubMed ID: 8583329
[TBL] [Abstract][Full Text] [Related]
24. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
25. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.
Krenning EP; Kwekkeboom DJ; de Jong M; Visser TJ; Reubi JC; Bakker WH; Kooij PP; Lamberts SW
Semin Oncol; 1994 Oct; 21(5 Suppl 13):6-14. PubMed ID: 7992084
[No Abstract] [Full Text] [Related]
26. Mack Forster Award Lecture. Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients.
Virgolini I
Eur J Clin Invest; 1997 Oct; 27(10):793-800. PubMed ID: 9373755
[TBL] [Abstract][Full Text] [Related]
27. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
28. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; deHerder WW; vanEijck CH; Kwekkeboom DJ; deJong M; Pauwels S
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S219-23. PubMed ID: 10604135
[TBL] [Abstract][Full Text] [Related]
29. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
[TBL] [Abstract][Full Text] [Related]
30. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
Reubi JC
J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054
[TBL] [Abstract][Full Text] [Related]
31. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
33. Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats.
Breeman WA; de Jong M; Bernard B; Hofland LJ; Srinivasan A; van der Pluijm M; Bakker WH; Visser TJ; Krenning EP
Anticancer Res; 1998; 18(1A):83-9. PubMed ID: 9568060
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
Reubi JC; Waser B; Laissue JA; Gebbers JO
Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
[TBL] [Abstract][Full Text] [Related]
35. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology.
Cascini GL; Cuccurullo V; Mansi L
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):24-36. PubMed ID: 20168284
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
[TBL] [Abstract][Full Text] [Related]
37. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
38. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin receptor imaging with 123I-Tyr3-Octreotide.
Lamberts SW; Reubi JC; Bakker WH; Krenning EP
Z Gastroenterol; 1990 Sep; 28 Suppl 2():20-1. PubMed ID: 1980773
[TBL] [Abstract][Full Text] [Related]
40. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).
Faglia G; Bazzoni N; Spada A; Arosio M; Ambrosi B; Spinelli F; Sara R; Bonino C; Lunghi F
J Clin Endocrinol Metab; 1991 Oct; 73(4):850-6. PubMed ID: 1653785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
